Objective-There are several known monogenic causes of high and low high-density lipoprotein cholesterol (HDL-C) levels, but traditional sequencing studies have had limited success in identifying mutations in the majority of individuals with extreme HDL-C levels. The aim of this study was to assess the power of a targeted high-throughput sequencing strategy to elucidate the genetic basis of extreme HDL-C phenotypes. Approach and Results-We sequenced 195 genes with either established or implicated roles in lipid and lipoprotein metabolism plus 78 lipid-unrelated genes in patients with HDL-C <1st (n=40) or >99th (n=40) percentile values, and the results were compared with those of 498 individuals representative of the Dutch general population and 95 subjects with normal HDL-C (between 40th and 60th percentile values). The extreme HDL cohort carried more rare nonsynonymous variants in the lipid geneset than both the general population (odds ratio, 1.39; P=0.019) and normal HDL-C (odds ratio, 1.43; P=0.040) cohorts. The prevalence of such variants in the lipid-related and lipid-unrelated genesets was similar in the control groups, indicative of equal mutation rates. In the extreme HDL cohort, however, there was enrichment of rare nonsynonymous variants in the lipid versus the control geneset (odds ratio, 2.23; P<0.0001), and 70% of the lipidrelated variants altered conserved nucleotides. The lipid geneset comprised 4 nonsense, 10 splice-site, and 8 coding indel variants, whereas the control geneset contained only 1 such variant. In the lipid geneset, 87% and 28% of the patients carried ≥2 and ≥5 rare variants.
T here is unequivocal evidence that low levels of plasma high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk of cardiovascular disease. 1 This knowledge, combined with evidence from experimental studies that HDL exerts many beneficial effects, 2 has fueled the development of drugs to increase HDL-C levels in plasma to reduce cardiovascular disease risk. 3 However, recent failures of drugs that target HDL-C levels, 4 combined with evidence that HDL might not causally be related to cardiovascular disease, 5 underscore the necessity of reevaluating the currently used strategies to intervene in HDL metabolism and a need to develop methods to monitor clinically relevant physiological effects of HDL beyond HDL-C plasma levels. 6, 7 The strategies that have been developed to raise HDL-C levels find their origin in the unraveling of the molecular origin of extreme HDL-C levels in humans. For example, the finding that loss-of-function cholesteryl ester transfer protein (CETP) mutations are a cause of hyperalphalipoproteinemia 8 led to the development of CETP inhibitors. It is noteworthy, however, that the molecular basis of extreme HDL-C phenotypes is poorly understood and that mutations in the main HDL candidate genes (APOA1, lecithin-cholesterol acyltransferase (LCAT), ABCA1, CETP, SCARB1, LIPG, and LIPC) explain extreme HDL-C levels in only a few percent of the individuals studied. [9] [10] [11] [12] [13] [14] The question addressed by the current study is whether very high or low HDL-C levels are associated with mutations in single genes or in multiple genes. Genomewide association studies (GWAS) have in this regard shown that common variants with small effect sizes only explain a small proportion of the heritability of plasma lipid levels. 15, 16 July 2013 This promotes speculation that (multiple) rare variants with moderate-to-large effect sizes may contribute to the missing heritability. 17 Indeed, several investigators have resequenced individual or small batches of candidate genes and observed a higher number of rare variants in individuals with extreme hypertriglyceridemia. 18, 19 Recent small-scale studies have also shown that some individuals carry multiple mutations in different genes, with established roles in lipid metabolism in families with apparent Mendelian forms of dyslipidemia. 14, 20 Since the start of large-scale GWAS in 2008 until to date, the number of candidate genes associated with plasma lipid phenotypes has steadily increased. These studies have underscored that most candidate genes affect multiple lipoprotein traits, and this is especially true for genes affecting HDL and triglyceride (TG) metabolism. 16 With this in mind, we set out to assess the burden of rare variants in 195 lipid-associated genes in individuals with HDL-C levels in the range observed in heterozygotes for Mendelian disorders of HDL metabolism.
Materials and Methods
Materials and Methods are available in the online-only Supplement. We studied 40 individuals with very low and 40 with very high HDL-C levels (<1 st and >99 th percentile for age and gender) from general patient population in the center of the Netherlands. Written informed consent was obtained and the study protocol was approved by the IRB. Coding sequence and exon-intron boundaries of 195 lipid-related genes (including 97 genes identified through meta-analysis of GWAS 16 data; Table I in the online-only Data Supplement) and 78 lipid-unrelated genes (with -proposed-roles in coagulation; Table II in the online-only Data Supplement) were sequenced using Agilent SureSelect custom capture library on the Illumina HiSeq 2000 platform.
Control cohorts were unrelated individuals representative of the Dutch general population (n=498) sequenced in the Genome of the Netherlands project (GoNL; http://www.nlgenome.com) and a selected subpopulation (n=95) of GoNL cohort with normal HDL-C levels (between 40 th and 60 th percentile).
Results

Characteristics of the Extreme HDL-C Cohort
The characteristics of 40 individuals with HDL-C levels <1st percentile and 40 individuals with HDL-C >99th percentile (for age and sex), as well as representatives of the Dutch general population (Genome of The Netherlands [GoNL] cohort), are shown in Table 1 . 21 There were no significant differences in mean ages and smoking history between the low and high HDL groups. The low HDL group, however, had statistically significant higher body mass index compared with the high HDL groups (P<0.0001). Compared with the GoNL cohort, the low HDL-C group had >50% lower HDL-C and >90% higher serum TG (both men and women). Conversely, the men in the high HDL-C group had 92% higher HDL-C and 41% lower TG than GoNL individuals. The corresponding values in women were similar, 114% higher HDL-C and 43% lower TG. Although the patients' referral basis to a physician was not used for inclusion into the current study, the low HDL-C group had higher incidences of diabetes mellitus and cardiovascular disease compared with the high HDL-C group (P<0.001 and P<0.01, respectively).
By design, HDL-C levels in the low HDL-C group were in the range typically observed in heterozygote individuals with deleterious APOA1, 22 LCAT, 11 and ABCA1 9,22 mutations, and such values were accordingly rare in the representative Dutch general population ( Figure I in the online-only Data Supplement). Similarly, HDL-C levels in the high HDL group were comparable with those observed in heterozygotes for deleterious CETP, 14 SCARB1, 23 and GALNT2 14, 24 mutations. We thus anticipated that individuals enrolled in this study would carry mutations in these genes and that their identification would serve as positive control for sensitivity of variant detection. Of note, the lipid profiles of several individuals were close to those observed in patients with homozygote or compound heterozygote mutations in the aforementioned genes ( Figure II in the online-only Data Supplement). *When untreated lipid values were not available, estimated baseline LDL-C values were calculated based on the potential of cholesterol-lowering therapy that was used. 21
Rare Variants in Lipid Geneset and Lipid-Unrelated Genes
As summarized in Table III in the online-only Data Supplement, we obtained sequences for 99.23% of the targeted region. Throughout the article, rare variants denote nonsynonymous (eg, missense, nonsense, splice-site) variants, with a minor allele frequency of <0.5% in the GoNL sample. Complete annotated lists of rare variants identified in all 80 HDL patients and their frequencies in the Dutch general population, as well as participants of the Exome Sequence Project, 25 are presented in Tables IV (lipid geneset) and V (control geneset) in the online-only Data Supplement.
The numbers of rare nonsynonymous variants identified in each of the studied cohorts are shown in Table VI in the online-only Data Supplement. In the extreme HDL-C cohort, for example, we identified 296 rare variants, including 8 coding indels, in the lipid geneset. In Table VII in the onlineonly Data Supplement, the burden of rare variants per gene is listed. Interestingly, GWAS lipid genes are among genes with the highest burden of rare variants.
Extreme HDL-C Levels Are Associated With a Higher Number of Rare Variants in Lipid-Related Genes
Comparisons between different cohorts or genesets were performed after correcting for the number of individuals studied and the number of nucleotides sequenced in the 2 genesets.
We first compared the frequency of rare variants in the extreme HDL cohort with the 2 control cohorts. The prevalence of rare variants in the lipid geneset was significantly higher in the extreme HDL cohort compared with the normal HDL cohort (odds ratio [OR], 1.43; confidence interval, [CI], 1.02-2.02; P=0.040) and Dutch general population (OR, 1.39; CI, 1.06-1.82; P=0.019; Figure 1A ). In a second step, we compared the number of rare variants in the lipid geneset and lipid-unrelated genes, assuming an equal mutation rate in both genesets in control cohorts. Indeed, no differences in frequency of rare variants between the 2 genesets were present in the general population sample (OR, 0.91; CI, 0.81-1.02; P=0.10) and the normal HDL cohort (OR, 1.05; CI, 0.79-1.39; P=0.74; Figure 1B ). Furthermore, on comparing the frequency of rare variants in the lipid geneset versus the lipid-unrelated genes in ≈3400 participants of the Exome Sequence Project, 25 we found that the frequency of such variants in the lipid geneset was lower, not higher, than the lipid-unrelated geneset (OR, 0.82; CI, 0.80-0.84; P<0.0001; Figure III in the online-only Data Supplement). In marked contrast, the extreme HDL-C cohort carried a significantly higher number of rare variants in the lipid geneset compared with the lipid-unrelated genes (OR, 2.23; CI, 1.58-3.16; P<0.0001; Figure 1B ). Thus, collectively, the first and second step analyses indicate that rare variants in lipidrelated genes are associated with extreme HDL-C phenotypes.
Rare Variants in Established HDL Genes Are Casually Related to Extreme HDL-C Phenotypes
As anticipated, the 12 well-established HDL genes 26 were significantly enriched for rare variants (OR, 2.46; CI, 1.37-4.44; P<0.005; Figure 1C ; Table VIII in the online-only Data Supplement): 16 variants in ABCA1, ABCG1, LCAT, CETP, LIPG, and LIPC ( Table 2) were identified in 13 individuals. As indicated in Table 2 , 4 of these variants were previously shown to be functional, 11, 27, 28 and our analysis of the 2 novel LCAT variants revealed a significant loss of enzymatic activity in plasma of the respective patients ( Figure IV in the online-only Data Supplement). These data indicate that rare variants in ). All data were corrected for the number of individuals studied. B, Individuals with extreme HDL-C levels have an enrichment of rare variants in the lipid geneset compared with the lipid-unrelated geneset. In the normal HDL cohort and the Dutch general population, such enrichment was not observed. All data were corrected for the size of target regions (number of nucleotides). C, Enrichment of rare variants in different gene subsets of the lipid geneset compared with the control geneset in the cohort of patients with extreme HDL-C. Genes with established roles in HDL-C metabolism are ABCA1, ABCG1, APOA1, APOM, ATP5B, CETP, GALNT2, LCAT, LIPC, LIPG, PLTP, and SCARB1. *Excludes genes with established roles in HDL-C metabolism. HDL (n=95), non-HDL (n=100), genome-wide association studies (GWAS; n=97), and non-GWAS (n=98) lipid genes are defined in Table I the established HDL genes are casually related to the extreme HDL-C phenotypes in our patient cohort and that, consistent with previous studies, 9, 11, 29 most of the affected individuals did not have a rare variant in a well-established HDL gene.
Rare Variants in GWAS and Non-HDL Lipid Genes Are Associated With Extreme HDL-C Phenotypes
We next compared the number of rare variants found in the distinct subsets of genes within the lipid geneset ( Table I in the online-only Data Supplement) with those in the lipidunrelated genes ( Figure 1C ; Table VIII in the online-only Data Supplement). Compared with the lipid-unrelated genes, the extreme HDL cohort exhibited an overrepresentation of rare variants in both the GWAS 16 and non-GWAS subsets of lipid genes (OR, 2.09; CI, 1.45-3.01; P<0.0001 and OR, 2.40; CI, 1.67-3.46; P<0.0001, respectively). We also discriminated between genes assigned to HDL (n=95) and non-HDL (n=100) groupings ( Table I in the online-only Data Supplement) and found that both genesets were significantly enriched for rare variants compared with the lipid-unrelated genes (OR, 2.20; CI, 1.53-3.18; P<0.0001 and OR, 2.62; CI, 1.57-3.25; P<0.0001, respectively; Figure 1C ; Table VIII in the online-only Data Supplement). The breakdown of the number of variants in the HDL and non-HDL genes in the lipid geneset in the extreme HDL patient group is presented in Figure 2A . Keeping in mind that we found many variants in well-established HDL genes that are known to be functional ( Table 2) , these results suggest that it is likely that a substantial proportion of the rare variants found in HDL genes, as well as those regulating low-density lipoprotein cholesterol and TG metabolism, may also be causally involved in regulating HDL-C levels.
Eighty-Seven Percent of Patients With Extreme HDL-C Carry ≥2 Rare Variants
Although only 1 individual in the extreme HDL cohort carried no variant in the lipid geneset, >87% of the individuals carried ≥2 rare and 28% of the individuals carried ≥5 such variants ( Figure 2B ). When speculating on the functionality of the rare variants identified, it is of note that almost 70% of the missense variants concern nucleotides that are conserved across species (phastCons score >0.5). Potential functionality of the variants in the lipid geneset is further strengthened by the finding that 22 variants (nonsense, splice-site, and coding indel) are predicted to alter the coding capacity of the encoded gene products in a major way (Table 3) , whereas only 1 such variant was identified in the lipid-unrelated genes ( Table V in the online-only Data Supplement). Combined, these data are suggestive of a polygenic origin for the extreme HDL-C levels in most members of our cohort of patients.
Discussion
Twin studies have shown that plasma HDL-C levels are 50% to 60% heritable. 30 Common gene variants have long been anticipated to contribute to this heritability, but GWAS have recently taught us that common variants can currently only explain ≤15% of this heritability. 15 This notion has led to the concept of a rare allele model in which multiple rare variants Figure IV with moderate-to-large effect on the phenotype play a role in the heritability of the complex phenotypes. 17 When trying to explain very extreme HDL-C levels in humans, several well-known monogenic origins have to be considered: loss of APOA1, LCAT, or ABCA1 gene function is known to cause HDL deficiency, [31] [32] [33] whereas a loss of CETP or LIPC causes hyperalphalipoproteinemia. 8, 34 More recently, heterozygosity for mutations in LIPG, SCARB1, and GALNT2 was also shown to cause high HDL-C levels. 14, 23, 24, 29 However only few patients with extreme HDL-C levels carry mutations in any of these genes, [9] [10] [11] [12] [13] [14] suggesting that deleterious variants in other, hitherto unsuspected, genes might explain some of the missing heritability. It is noteworthy, however, that no major HDL gene has been identified since the discovery of the ABCA1 in 1999. With this in mind, we set out to unravel the genetic background of extreme HDL-C levels.
Deleterious effect of these variants on LCAT activity is shown in
Multiple Rare Variants in Lipid-Related Genes of the Extreme HDL Cohort
As a first step, we assessed the number of rare variants in 195 lipid-related genes in 80 patients with extreme HDL-C and 2 control cohorts. Comparison revealed significantly more rare variants in lipid-related genes in the extreme HDL cohort. To validate this finding, we compared the number of rare variants in the lipid geneset and a control set of lipid-unrelated genes. In the control cohorts, we observed no difference in the frequency of rare variants in the lipid genesets and lipid-unrelated genesets after adjustment for the number of nucleotides sequenced in each of the genesets. This indicates that mutation rates in each of the 2 genesets were similar in controls. However, in the extreme HDL cohort, we identified a significant >2-fold increase of rare variants in the lipid geneset.
Are the Identified Rare Variants Functional?
In the patients with extreme HDL-C levels, we identified 3 splice-site and 13 missense variants in genes with established roles in HDL metabolism (Table 2) . Specifically, 2 patients with low HDL-C carried ABCA1 variants within canonical splice sites of exon-intron boundaries. Both these splice-site variants involved highly conserved nucleotides (phastCons score=1). The third splice-site variant was found in CETP in a patient with high-plasma HDL-C levels and is very likely to be functional based on previous findings. 35 The same is true for the p.Ala291Asp substitution found in a second patient with high HDL-C; this variant is not only found at an evolutionary conserved nucleotide (phastCons score=1) but also resides in the center of the cholesteryl ester binding tunnel of this lipid transfer protein. 36 We also identified 2 missense variants in LIPC, both of which were previously detected in families with hepatic lipase deficiency 27, 28 and subsequently confirmed to be deleterious by functional analyses. 37 Similarly, we identified 2 LCAT variants, previously shown to be deleterious, 11 and show that the 2 novel LCAT variants found in the current study are associated with loss of LCAT catalytic activity in the plasma of the respective patients ( Figure IV in the online-only Data Supplement).
The identification of multiple known and novel functional mutations in well-established HDL genes in this study underscores that our approach to identify molecular causes of very low or very high HDL-C in this cohort was sound. With this in mind, it is reasonable to assume that the rare variants identified in other candidate genes, mainly identified through GWAS, could also be causally related to the extreme HDL-C phenotypes, but of course functional studies need to be performed to provide ultimate proof.
A Possible Polygenic Origin of Extreme HDL-C Levels
After recent insight into the complex background of hypertriglyceridemia, 38 the current study indicates that this may also hold true for extreme HDL-C phenotypes. Until recently, we and others have limited our insight by sequencing 1 or at most several candidate genes to try to explain extreme HDL-C phenotypes. With next-generation sequencing, however, we are confronted with possible functional variants in an increasing number of genes. The current study provides interesting examples, illustrating the complexity of the genetic architecture of extreme HDL-C levels.
Fitting the old concept of a possible monogenic origin for extremely low HDL-C, we identified a single splice-site variant in ABCA1 and a functional missense variant in LCAT in 2 patients with low HDL-C levels ( Table 2 , patient IDs: LM28 and LM31). However, these patients belonged to the small group of 9 individuals in whom only 1 rare variant was found in all 195 sequenced lipid-related genes. All other patients (87%) carried ≥2 rare variants, whereas 28% of the patients carried ≥5 rare variants. Although we have not shown that all of the variants identified are functional, the numbers of gene variants in some individuals suggest that their extreme HDL-C level is of complex polygenic origin. Examples are a single individual with low HDL-C (patient LM26) heterozygote for rare variants in 12 lipid-related genes (ABCA1, ABCG1, ABCG8, COL18A1, LIPG, LPL, LRP4, MSL2, NCAN, PLEC, SELP, WWOX), including 7 variants predicted to be deleterious when using in silico analysis. Similarly, another individual with high HDL-C level (HM47) carried 14 rare variants in 13 lipid-related genes (AMAC1L2, APOB, BMP1, CETP, CUBN, FUT2, GYS1, IGF2R, LPA, NLRC5, PLEC, SULF2, TMED3), including 6 potentially deleterious variants ( Table IV in The current study clearly illustrates that even very extreme HDL-C phenotypes can have a polygenic origin and suggests that this may be rooted in the diversity of the processes in various organs, as well as circulation and vascular bed, that govern serum cholesterol and triglyceride levels. This complexity may explain why efforts to identify new HDL genes through linkage analyses (in combination with exome sequencing) have not been successful because obtaining significant/confirmed logarithm of odds (LOD) scores can be difficult in the face of genetic (locus and allelic) heterogeneity, 39 which characterizes the extreme HDL-C cohort studied here.
Rare Variants in Genes Not Directly Associated With HDL Metabolism
In this study, we did not limit ourselves to genes that are only reported to be associated with HDL metabolism. The rationale for this choice is that in many cases it is simply not possible to exclusively mark genes for HDL, triglyceride, or low-density lipoprotein metabolism. A few examples include the following: loss of CETP affects the concentration of all circulating lipoproteins, 40 whereas a loss of LCAT causes HDL deficiency but also hypertriglyceridemia. 41, 42 Homozygous lipoprotein lipase deficiency not only causes hypertriglyceridemia but also HDL deficiency. 43, 44 Indeed, the problem with gene annotation is illustrated by the fact that in 1 well-known GWAS, the most prominent HDL gene, APOA1 is denoted as a gene, with plasma triglycerides as first lipid trait. 16 Nonetheless, it is still interesting that our study shows that although the participants were selected solely on the basis of their extreme HDL-C levels, ≈50% of the variants we identified were in 58 genes traditionally associated with plasma total cholesterol, triglycerides or low-density lipoprotein cholesterol levels ( Figure 2A ; Table IV in the online-only Data Supplement). In some cases, the underlying molecular mechanism could be *Genes with proposed role in lipid metabolism identified by meta-analysis of genome-wide association studies 16 data.
readily clarified. For example, 2 splice-site variants in APOC3 most probably gave rise to increased HDL-C in these patients as a direct consequence of enhanced lipoprotein lipase-mediated plasma triglyceride hydrolysis. 45 For other high-impact rare variants (nonsense, splice-site, and coding indel) in PCSK5, PLEC, ABCA8, C5orf35, and CITED5 (Table 3) , we are currently investigating how they could have an impact on HDL-C metabolism.
Limitations of the Study
To increase the statistical power of our analyses, we combined individuals at both ends of the plasma HDL-C level distribution, which creates an artificial grouping. Therefore, a similarly designed approach, with considerably larger sample that compares the individual genetic architectures of hyperalphalipoproteinemia and hypoalphalipoproteinemia, is warranted. In our analyses of the extreme HDL cohort, we also elected to study genes associated with lipid metabolism, in general, rather than restricting the focus to only HDL-related entities, given the strong interplay between HDL-and non-HDL-C and triglyceride metabolism. Indeed, we recognize it is often not possible to label lipid genes with unique lipid trait tags [40] [41] [42] [43] [44] and that functional analyses will be required to draw definitive conclusions regarding the mechanisms by which rare variants in the non-HDL genes may contribute to hyperalphalipoproteinemia and hypoalphalipoproteinemia. For most genes studied, there is also limited information on whether a loss-or gain-of-function mutation would increase/decrease HDL-C. Hence, functional studies are required to assess the contribution of each gene and associated variant on HDL metabolism. In some cases, segregation analysis in families of the index patients may also help to resolve whether and how genotypes correlate to the phenotype. However, for individuals with multiple variants (eg, individuals with 12 or 14 rare variants described in this study), resolving genotype-phenotype correlation, if not impossible, will practically be very difficult.
Conclusions
This study shows that extreme HDL-C phenotypes are not necessarily of monogenic origin. The data in fact suggest that multiple rare variants can contribute to the heritability of extreme plasma HDL-C levels. In addition, the data provide support to perform functional studies to elucidate how rare variants in newly proposed candidate genes (mostly from GWAS) exert their effects.
